Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

By J. Gallant, S. Staszewski, A. Pozniak, E. Dejesus, J. Suleiman, Michael D. Miller, D. Coakley, B. Lu, J. Toole, A. Cheng. Journal of the American Medical Association (JAMA), 2004

1,474 citations recorded by the source corpus.

Subfields: Emergency Medicine, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/80b88044ace9b32b14d780fddb7baeba639176e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Q. Cao
E. Clercq
Song Chen
A. Holý
J. Routy
X. Gui
R. Qaqish
T. Brown

Citations in the corpus

Acyclic nucleoside phosphonates: a key class of antiviral drugs (2005, methodology): “3c , the combination of TDF with 3TC and efavirenz (EFV) was compared with that of stavudine with 3TC/EFV: both combination 'arms' were found to be equally effective in reducing the viral load over a period of 48 weeks, and this equivalence in efficacy was sustained through 144 week”
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. (2010, neutral): “and several renal toxicities [33–35].”
Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation (2019, result): “For nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs), dyslipidemia has been associated with exposure to stavudine, zidovudine, and abacavir, whereas tenofovir and lamivudine showed minimal or even a favorable lipid influence.([16]) In the NNRTIs, efavirenz has been associated with inc”
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review (2006, background): “In a large randomized, double-blinded trial comparing the safety and efficacy of tenofovir to stavudine with a lamivudine and efavirenz backbone (n1⁄4 602) [4], significant BMD reductions in the spine and hip were observed in both treatment groups over the 144-week study interval.”